Preparing COVID-19 Vaccine Moderna syringes for administration at end user locations

Sue Dickinson, Director of Pharmacy, Regional Drug & Therapeutics Centre (Newcastle)Published Last updated See all updates

Standard Operating Procedure for preparing Moderna Spikevax® COVID-19 Vaccine syringes for administration at end user locations in primary care.


The Conditions of Authorisation for Moderna Spikevax® COVID-19 vaccine have been amended to enable transportation at 2-8C of unopened vials in multiple journeys up to 12 hours in total.

Staff at all sites should discuss their plans with their clinical leads and responsible pharmacists as appropriate prior to transportation of any vaccine type.



Other handling content for PCNs

Other COVID-19 vaccines resources

What to do if you still have questions

If you still have questions you can get in touch with us. However, please first read our service remit; and if you still think we can help, use the email address below.

We're supporting healthcare professionals in England with pharmaceutical aspects of the COVID-19 vaccination programme; read our service remit to find out more.
If you're a healthcare professional in England, get in touch with us if you still have questions

Change history

  1. MVH8 Section 5.3.17 Removal of outdated Foundry codes 6
  2. Data now available to support transportation of one or more thawed vials in liquid state for up to 12 hours at 2°C to 8°C (within the 30 days shelf life at 2°C to 8°C). SOP and supporting documents reinstated. Reference to use with vials received frozen removed
  3. The name of the vaccine has changed to Spikevax®
  1. SOP suspended following confirmation that Moderna COVID-19 vaccine should not be used in mobile or roving settings if delivered in the thawed state
  1. Published